期刊文献+

中美注射剂标签信息比较及安全启示

Information Comparison and Security Implications of Injection Labeling in China and the United States
下载PDF
导出
摘要 美国注射剂标签安全性信息和中国存在较多的不同之处,值得国内标签设计者学习借鉴。本文将中美两国注射剂标签实例按照设计要素进行比较,分析两国注射剂标签信息的不同之处,为完善我国标签规范化管理和格式要求提供参考,为国内注射剂标签设计提供实例参考。 There are many differences with the safety information in theof injection labeling between China and the US,which is worth of learning for the label designer in China.By comparing the design elements with instances of injection labeling in China and the United States,this study analyzed the differences of information on the injection labeling between the two countries.The aim is to provide a reference for improving the normalization and format requirements of labeling in our country,and provide real case reference for the design of injection labeling.
作者 金宏 付莉娜 许静玉 吕昂 陶巧凤 JIN Hong;FU Li-na;XU Jing-yu;Lü Ang;TAO Qiao-feng(Zhejiang Center for Drug and Cosmetic Evaluation,Hangzhou 310012,China;Hangzhou First People's Hospital,Hangzhou 310006,China;Zhejiang Institute for Food and Drug Control,Hangzhou 310052,China)
出处 《中国合理用药探索》 CAS 2021年第1期15-21,共7页 Chinese Journal of Rational Drug Use
关键词 注射剂 标签 实例 信息对比 安全 injection labeling instances information comparison security
  • 相关文献

参考文献4

二级参考文献11

  • 1FDA. Warning on tendon injuries with fluoroquinolone antibiotics [ EB/OL]. http://www, fda. gov, 2008 -07 -08.
  • 2FDA. Chantix and Zyban to get Boxed Warning on serious mental health events[ EB/OL]. http://www, fda. gov, 2009 -07 -01.
  • 3FDA. Drug safety communication: New warning agninst use of ter- butaline to treat preterm labor [ EB/OL ]. http ://www. fda. gov, 2011 - 02 - 17.
  • 4Shumaker SA, Leganlt C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post- menopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial [ J]. JAMA, 2003,289:2651 -2662.
  • 5FDA. Estrogen and estrogen/progestin drug products to treat vasonm- tor symptoms and vulvar and vaginal atrophy dations for clinical evaluation [ EB/OL ]. http://www, fda. gov, 2003 - 01 - 02.
  • 6Sturdee DW, Pines A, Archer DF, et al. Updated IMS recommenda- tions on postmenopausal hormone therapy and preventive strategies for midlife health [J]. Climacteric, 2011,14:302 -321.
  • 7Kelly Smith,无.产品标签对药物警戒的影响[J].中国药物警戒,2009,6(8):511-512. 被引量:1
  • 8黄丹丹,谢学建.如何看待药品说明书之外的用法[J].中国药业,2012,21(18):57-58. 被引量:4
  • 9张璐,张伏.目前药品标签和说明书存在的不足及对策[J].中国药业,2013,22(20):7-8. 被引量:5
  • 10王敏,于珊珊,王中磊,于红波,周颖真,吕彦广,杜凤霞.解放军第302医院高警示药品的管理策略[J].中国医院用药评价与分析,2017,17(2):152-153. 被引量:11

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部